Aurinia Pharmaceuticals (AUPH)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from AUPH's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Aurinia Pharmaceuticals's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $46M | $134M | $176M | $235M | $283M |
| Net income | -$181M | -$108M | -$78M | $6M | $287M |
| Free cash flow | -$159M | -$80M | -$33M | — | — |
| EPS (diluted) | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Operating margin | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own AUPH
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Trimmed | $16M | 0.01% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $2M | 0.00% | Q2 2026 |
| Ric Dillon Diamond Hill Capital Management |
Held | $2M | 0.01% | Q2 2026 |
Insider buying
Open-market purchases by Aurinia Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 27, 2026 | Kevin Tang |
516,439 | $13.99 | $7M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when AUPH trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Aurinia Pharmaceuticals insiders buying the stock?
1 open-market insider purchase of AUPH in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Aurinia Pharmaceuticals?
3 of the superinvestors Investingly tracks hold AUPH in their latest 13F, including Cliff Asness, Joel Greenblatt, Ric Dillon.
Companies like Aurinia Pharmaceuticals
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.